EGFR and lung cancer: It has been recently demonstrated that the EGFR inhibitors gefitinib and erlotinib enhance the susceptibility to NK cell mediated lysis of A549, NCI-H23 and SW-900 lung cancer cell lines [26] by the induction of ULBP1 (a ligand of the NK cell activation receptor NKG2D).